What antibiotic is effective against Enterococcus faecium, particularly vancomycin-resistant strains?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Antibiotic Treatment for Enterococcus faecium Infections

For Enterococcus faecium infections, linezolid is the most effective treatment option for vancomycin-resistant strains, while ampicillin remains the drug of choice for ampicillin-susceptible strains. 1, 2

First-Line Treatment Algorithm

Step 1: Determine Susceptibility Pattern

  • For ampicillin-susceptible E. faecium: Use ampicillin as first-line therapy 1
  • For vancomycin-susceptible but ampicillin-resistant E. faecium: Use vancomycin 2
  • For vancomycin-resistant E. faecium (VRE): Use linezolid 600 mg IV/PO every 12 hours 2, 3

Step 2: Alternative Options for VRE

  • Daptomycin 8-12 mg/kg/day IV is recommended as an alternative for VRE bacteremia 2, 4
  • Quinupristin-dalfopristin (Synercid) inhibits growth only in E. faecium (not E. faecalis) 2, 5
  • Tigecycline 100 mg IV loading dose followed by 50 mg IV every 12 hours for intra-abdominal infections 2

Clinical Considerations

Antimicrobial Resistance Patterns

  • E. faecium is more likely to be resistant to multiple antibiotics compared to E. faecalis 1, 6
  • Five phenotypes of vancomycin resistance (vanA through E) exist in enterococci, with vanA and vanB genes found primarily in E. faecium 2
  • Vancomycin-resistant E. faecium is often multidrug-resistant, creating significant treatment challenges 2, 7

Combination Therapy for Severe Infections

  • For severe VRE infections, consider combination therapy with daptomycin plus ampicillin or ceftaroline for potential synergistic effects 1, 8
  • Double β-lactam combinations (imipenem and ampicillin or cephalosporins plus ampicillin) have shown synergistic bactericidal activity against some E. faecalis strains 2

Special Situations

Urinary Tract Infections

  • For uncomplicated VRE urinary tract infections, consider:
    • Fosfomycin 3 g PO single dose 2
    • Nitrofurantoin 100 mg PO every 6 hours 2
    • High-dose ampicillin (18-30 g IV daily in divided doses) or amoxicillin 500 mg PO/IV every 8 hours if susceptible 2

Endocarditis

  • For endocarditis caused by vancomycin-resistant E. faecium, linezolid therapy resulted in cure of 77% of cases 2
  • Daptomycin at higher doses (10-12 mg/kg/day) may be more effective for serious infections like endocarditis 1, 4

Common Pitfalls and Monitoring

  • Linezolid resistance can emerge during therapy, particularly with prolonged use (>14 days) 9, 10
  • Monitor for bone marrow suppression and neuropathy with prolonged linezolid use 1
  • Enterococci are intrinsically resistant to cephalosporins when used as monotherapy 1
  • Daptomycin monotherapy may lead to treatment failure in severe infections; consider combination therapy for better outcomes 1, 8
  • The FDA has approved linezolid specifically for the treatment of vancomycin-resistant Enterococcus faecium infections, including cases with concurrent bacteremia 3

Duration of Therapy

  • For uncomplicated infections: 7-14 days 1
  • For bacteremia or endocarditis: 14-28 days 3
  • For complicated infections: Duration should be based on clinical response 2

References

Guideline

Antibiotic Treatment for Enterococcus faecium Wound Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Enterococcus faecalis Infections in Prostatic Abscesses

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Management of multidrug-resistant enterococcal infections.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2010

Research

The emerging problem of linezolid-resistant enterococci.

Journal of global antimicrobial resistance, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.